The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A Novel Cyclohexene Derivative, Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), Selectively Inhibits Toll-Like Receptor 4-Mediated Cytokine Production through Suppression of Intracellular Signaling
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“PGN, poly(I:C), and CpG DNA were used as ligands for TLR2, -3, and -9, respectively (Takeuchi et al., 1999; Hemmi et al., 2000; Alexopoulou et al., 2001).”
BackgroundMethodRecognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein
Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., & Mathison, J. C. (1990) · Science · doi:10.1126/science.1698311 · Cited by 3,987
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80119-3 · Cited by 3,362
LPS induction of gene expression in human monocytes
Guha, M., & Mackman, N. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(00)00149-2 · Cited by 2,304
MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4
Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., & Kimoto, M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1777 · Cited by 2,185
Nitric oxide and superoxide in inflammation and immune regulation.
Guzik, T. J., Korbut, R., & Adamek-Guzik, T. (2003) · PubMed · Cited by 1,349
Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., & Akira, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6668 · Cited by 1,227
Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., & Seya, T. (2003) · Nature Immunology · doi:10.1038/ni886 · Cited by 1,207
Self-citationLPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF
Fitzgerald, K. A., Rowe, D. C., Barnes, B. J., Caffrey, D. R., Visintin, A., Latz, E., Monks, B., Pitha, P. M., & Golenbock, D. T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031023 · Cited by 1,193
Cited by
Signaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,388
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
The Pathogenesis of Sepsis and Potential Therapeutic Targets
Huang, M., Cai, S., & Su, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215376 · Cited by 776
Inflammation in intracerebral hemorrhage: From mechanisms to clinical translation
Zhou, Y., Wang, Y., Wang, J., Anne Stetler, R., & Yang, Q.-W. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.003 · Cited by 628
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors
Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.008 · Cited by 621
Matsunaga, N., Tsuchimori, N., Matsumoto, T., & Ii, M. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068064 · Cited by 597
Self-citationA randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
Self-citationTherapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Toll‐like receptor 4 in CNS pathologies
Buchanan, M. M., Hutchinson, M., Watkins, L. R., & Yin, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06736.x · Cited by 336
Toll-like receptors as targets in chronic liver diseases
Mencin, A., Kluwe, J., & Schwabe, R. F. (2009) · Gut · doi:10.1136/gut.2008.156307 · Cited by 329
Caspase‐4 mediates non‐canonical activation of the NLRP3 inflammasome in human myeloid cells
Schmid‐Burgk, J. L., Gaidt, M. M., Schmidt, T., Ebert, T. S., Bartok, E., & Hornung, V. (2015) · European Journal of Immunology · doi:10.1002/eji.201545523 · Cited by 315
TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain
Kawamoto, T., Ii, M., Kitazaki, T., Iizawa, Y., & Kimura, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.026 · Cited by 313
Self-citationSensing Gram-Negative Bacterial Lipopolysaccharides: a Human Disease Determinant?
Munford, R. S. (2008) · Infection and Immunity · doi:10.1128/iai.00939-07 · Cited by 189
Vila, I. K., Badin, P.-M., Marques, M.-A., Monbrun, L., Lefort, C., Mir, L., Louche, K., Bourlier, V., Roussel, B., Gui, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.062 · Cited by 165
Toll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
Toll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies
Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143
Sangineto, M., Ciarnelli, M., Cassano, T., Radesco, A., Moola, A., Bukke, V. N., Romano, A., Villani, R., Kanwal, H., Capitanio, N., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102846 · Cited by 142
Mayerhofer, R., Fröhlich, E. E., Reichmann, F., Farzi, A., Kogelnik, N., Fröhlich, E., Sattler, W., & Holzer, P. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.10.011 · Cited by 89
Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses
Meng, J. X., Zhang, Y., Saman, D., Haider, A. M., De, S., Sang, J. C., Brown, K., Jiang, K., Humphrey, J., Julian, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30461-x · Cited by 84
Song, D., Jiang, X., Liu, Y., Sun, Y., Cao, S., & Zhang, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00028 · Cited by 72
“TAK-242 is a specific inhibitor of TLR4 receptor and used as a positive control for comparison of the effect of AS (Li et al., 2006).”
MethodAmbrus-Aikelin, G., Takeda, K., Joetham, A., Lazic, M., Povero, D., Santini, A. M., Pranadinata, R., Johnson, C. D., McGeough, M. D., Beasley, F. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39805-z · Cited by 28
“Loss of membrane integrity as a result of caspase-1 mediated pyroptosis is signified by the appearance of the p10 component in cell supernatants of the TAK242 treated samples, but not in the emricasan treated samples.”
Result
Metadata
- Authors
- Ii, M., Matsunaga, N., Hazeki, K., Nakamura, K., Takashima, K., Seya, T., Hazeki, O., Kitazaki, T., & Iizawa, Y.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 69
- Issue
- 4
- Pages
- 1288-1295
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2162826697
- Cited by
- 377
- References
- 40
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.